Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05283382

Cannabidiol Effects on Learning and Anxiety

To examine the extent to which Cannabidiol (CBD) enhances fear conditioning extinction in college undergraduates who show elevated social anxiety. Undergraduates who display elevated social anxiety on standard assessments will be recruited at the University of Connecticut. All participants will be put in a standard fear conditioning paradigm where they are conditioned to fear a face that occasionally is followed by a shock to their wrist. The other face never is paired with a shock. After everybody learns this, half of the participants will receive 600 mg CBD Isolate Gel Capsules one time, and the other half will receive a placebo dose. Participants will then be presented with the faces with no shocks, and the rate and duration of extinction as measured by electrodermal response as well as subjective fear ratings via a visual analogue scale will be examined. It is hypothesized that participants that receive CBD will display enhanced extinction compared to the placebo group, as evidenced by reduced electrodermal response and reduced visual analogue fear ratings.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

University of Connecticut

Storrs, Connecticut, 06269-1020, United States

Location status: Recruiting

Location contact

Robert Astur

CONTACT

[email protected]

203-236-9938

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-50 years of age

Exclusion criteria

  • Difficulties seeing a computer screen
  • Anyone currently taking CBD within the last 24 hours.
  • Anyone using any cannabis product within the last 24 hours.
  • Heart problems or heart disease
  • A neurological disorder such as epilepsy, stroke, multiple sclerosis, tumor, vascular malformations, aneurysm
  • Are currently pregnant or breast-feeding

Treatment and study plan

Cannabidiol Oral Product

Drug

Participants will receive a one-time dose of 600 mg Cannabidiol Isolate Gel Capsules in the form of six 100mg capsules.

Placebo

Other

Participants will receive a one-time dose of placebo capsules in the form of six capsules.

Primary outcomes

  1. Electrodermal activity

    Time frame: 20 minutes

    Electrodermal response as measured by galvanic skin response electrodes that are attached to two of the fingers via sticker electrodes. These passively measure the conductance of the sweat glands on the fingers.

Study contacts

Contact information is provided by the study sponsor or research team.

Robert Astur, PhD

CONTACT

[email protected]

2032369938

Sponsors and collaborators

Lead sponsor

University of Connecticut

Other

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Mar 17, 2022
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.